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Introduction
Endometrial carcinoma (EC) treatment currently relies on risk stratification systems based on clinicopathological parameters [1] . Histotype and grade, key parameters in the most popular stratification systems, have been shown to have poor reproducibility [2] [3] [4] [5] , resulting in pathologists often classifying similar tumours differently [6] . This has severely hampered the ability to refine prognostication or assess treatment efficacy [7] . Moreover, stage and lymphovascular space invasion (LVSI), parameters needed to assign or refine risk group, are only available after surgical staging, leading to risk models that are unable to inform decisions regarding surgical procedures. Taken together, these deficiencies have resulted in wide variations in how women with EC are managed (surgical and adjuvant therapy). There has been a call from the scientific community [7, 8] to improve the diagnosis and risk stratification of patients with EC using biologically informative diagnostic tools.
The Cancer Genome Atlas (TCGA) endometrial collaborative project discovered four distinct prognostic EC subtypes based on genomic abnormalities [9] that reflect EC tumor biology, raising the possibility of more precise guidance of surgery, adjuvant therapy, and disease surveillance. Inspired by these findings, we developed a simplified, pragmatic, molecular classifier, termed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), which identifies four molecular subtypes that are analogous but not identical to the four genomic subtypes described in TCGA [10] ; mismatch repair deficient (MMR-D), showing loss of one or more mismatch repair protein(s), corresponds to the hypermutated subtype; DNA polymerase epsilon (POLE), with mutations in the exonuclease domain in exons 9-14, corresponds to the ultramutated subtype; p53 abnormal (p53abn) demonstrating aberrant p53 immunohistochemical staining, corresponds to the copy number high subtype; and p53 wild-type (p53wt) corresponds to the copy number low subtype. In contrast to the TCGA methods that depend on fresh-frozen material and require costly and complex methodologies, ProMisE can be achieved on formalin-fixed, paraffin-embedded material using methods easily adopted in pathology labs at most cancer centers. Similar assays have been developed by the TransPORTEC international consortium, identifying four very similar molecular subtypes with distinct outcomes and high diagnostic reproducibility [11, 12] . Applicability of molecular classification to diagnostic specimens, i.e. biopsy and curettage, has been shown to be highly concordant with final hysterectomy specimens [13, 14] , thus providing information that could be used to plan the timing and extent of surgery.
Following the Institute of Medicine (IOM) guidelines for the development of Omics-based tests (http://nationalacademies. org/hmd/Reports/2012/Evolution-of-Translational-Omics/Repo rt-Brief.aspx) [15] , we previously reported on the 'discovery' [10] and 'confirmation' [16] cohorts encompassing over 450 cases. Herein, we applied ProMisE molecular classification to a large population-based cohort of consecutive ECs from an independent institution to validate this tool (validation cohort). This is the final step of the IOM guidelines before clinical evaluation, usually through prospective clinical trials.
Patients and methods

Study cohort, clinicopathological data, and outcomes
The validation cohort consisted of patients treated for primary EC at the Tübingen University Women's Hospital between 2003 and 2013. Methods used in this study were as previously described [10, 14, 16] .
Details on inclusion and exclusion criteria, as well as definitions used for collected clinicopathological parameters, outcomes and molecular methods, including tissue microarray construction and immunohistochemistry, DNA extraction, sequencing, and ProMisE molecular subgroup assignment are further detailed in the supplementary methods, available at Annals of Oncology online.
Statistical analysis
REMARK [17] reporting criteria were followed, with full description of statistical methods in the supplementary methods, available at Annals of Oncology online. Briefly, associations of clinicopathological parameters with ProMisE subtypes were compared using one-way analysis of variance and v 2 test. Univariable and multivariable survival analyses were carried out to assess the association of ProMisE and other clinicopathological parameters with overall survival (OS), disease specific survival (DSS), and progression free survival (PFS) using Kaplan-Meier and cox proportional hazard models. Hazard ratios with corresponding 95% CI's and Likelihood Ratio Test (LRT) P-values were reported. The discriminatory ability of models combining ProMisE and other clinicopathological parameters were compared using Harell's C-index. These models were developed in the previously described Vancouver cohort and assessed in the validation cohort. Concordance statistics comparing diagnostic and hysterectomy specimens were evaluated using Cohen's kappa (j), and per class sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were computed.
Results
Patient cohort
After chart and pathology review, 509 patients fulfilled inclusion criteria and underwent molecular testing. Of those cases 298 had available hysterectomy samples only, 55 diagnostic endometrial biopsy or curettage specimens only, and 156 had both diagnostic biopsy/curettage and hysterectomy specimens. Fifty-seven cases were excluded due to missing and/or uninterpretable molecular data (supplementary Figure S1 , available at Annals of Oncology online). The median overall observation time was 5.1 years, and median follow-up was 5.3 years (reverse Kaplan Meier).
Patient age at diagnosis ranged from 29 to 93 (median 65) years. The majority of cases (87.8%) were endometrioid histotype, 34 (7.5%) were serous, the rest were clear cell and mixed histology. Grade Figure 1A ). The spectrum of POLE EDMs identified in this cohort is provided in supplementary Table S1, available at Annals of Oncology online. A small proportion (1.8%) of patients had tumors that demonstrated more than one molecular feature, i.e. both a POLE EDM and p53abn, or mismatch repair abnormality (MMR-D) in addition to p53abn, however, the ProMisE decision tree dictates the order in which tumors are assigned to a specific molecular subtype, with the former example classified as POLE and the latter as MMR-D.
The univariable associations of ProMisE molecular subtypes with clinicopathological parameters are shown in Table 1 . Missing observations from clinicopathological features were not significantly associated with ProMisE subtypes except LVSI (P ¼ 0.049; supplementary Table S2 , available at Annals of Oncology online). With the exception of BMI, all clinicopathological features evaluated demonstrated significant associations with ProMisE subtypes. Consistent with previous findings, p53abn patients were older, with lower BMI, mostly serous, and diagnosed at a high stage and grade. They showed other aggressive characteristics such as myometrial invasion, positive lymph nodes and LVSI, resulting in an ESMO 2013 and 2016 high-risk assignment in 87% of the p53 abn cases. The subtype with the second most aggressive features was MMR-D, with myometrial invasion and LVSI comparable to p53abn tumours, and much greater than observed in women with POLE or p53wt ECs. The largest subtype, p53wt, was characteristically low-grade, low stage, endometrioid (99%) histotype, with 64% and 62% fitting the criteria of 'low-risk' by 2013 and 2016 ESMO criteria, respectively. Only 14% of women with POLE EDMs in this series were grade 3 when compared with 70% in the confirmation series [21] . This difference resulted in a high proportion of women with POLE EDMs designated 'low-risk' (74% and 67% by ESMO 2013 and 2016 criteria). The proportion of non-endometrioid (N ¼ 4), or advanced stage (N ¼ 3) disease was very small in the POLE subtype. One patient within the POLE subtype had a recurrence and death from EC. This patient was 66 years old with grade 3 endometrioid, stage IV disease with deep myometrial invasion, LVSI and high tumor burden.
Validating ProMisE as an independent prognostic marker
Univariable survival analyses revealed that all demographic, clinical, and pathological parameters known to be of prognostic importance in EC were significantly associated with clinical outcome in this cohort (Table 2) . Outcomes by molecular subtype were consistent with what was previously observed in the discovery and confirmation cohorts, with most favorable outcomes in the POLE subtype and the least in women with p53abn tumors, and the separation of the two intermediate survival curves with more favorable outcomes in p53wt when compared with MMR-D (log-rank P < 0.001; Figure 1B -D). A detailed breakdown of numbers and types of events (recurrences, deaths from disease) is given in supplementary Table S3 , available at Annals of Oncology online.
In multivariate survival analysis (Table 3) , adjusting for all known prognostic parameters available at time of diagnosis, ProMisE maintained its associations with progression-free (P ¼ 0.001) and disease-specific survival (P ¼ 0.03). The association with OS was not statistically significant (P ¼ 0.11). Adjusting for the effect of treatment on outcome (supplementary Table S4 , available at Annals of Oncology online), ProMisE remained a significant prognostic marker (P < 0.005) for both progression (P < 0.001) and disease-specific survival (P ¼ 0.029).
Comparing the hazard ratio for each molecular subtype across the different cohorts, we note the consistency in directionality of hazard (i.e. they tend to have improved or unfavorable hazard) and their comparability in terms of effect size. Variation seen in effect size could be attributed to sample size, which when small will increase variability and widen confidence intervals (supplementary Figure S2 , available at Annals of Oncology online).
To validate the ability of the ProMisE classifier to discriminate outcome, as was observed previously, we used model parameters that were previously obtained from the full Vancouver cohort (combining discovery and confirmation) [16] to predict outcome in current data, and compared their discrimination ability with respect to outcomes (OS, DSS, and PFS) as measured by the Harell's C-index. As noted in Figure 1E , the discrimination ability in this cohort was improved relative to the discovery and the confirmation cohorts. Similarly, we note that when ProMisE is augmented with other clinical parameters (available at time of diagnosis or following surgery), the C-index was further improved.
Comparison of ProMisE and ESMO
Crosstabulation of ProMisE molecular subtypes and ESMO 2013 risk groups demonstrates that although there are some subtypes that show substantial overlap with risk group category (e.g. most p53abn cases are ESMO high risk, and most POLE cases are low risk) these tools identify different women. There were ECs assigned as ESMO high-risk, as well as low-risk across all ProMisE subtypes with substantial diversity of ESMO risk groups within MMR-D and p53wt subtypes ( Figure 1F ).
Reliability of ProMisE in diagnostic specimens
We compared the agreement of molecular classification (ProMisE) between diagnostic (biopsy or curettage) and postsurgical staging specimens (hysterectomy) obtained from the same patient (N ¼ 156, supplementary Table S5A , available at Annals of Oncology online). Concordance metrics comparing diagnostic endometrial biopsy/curettings to final hysterectomy samples (the latter held as the 'gold standard') were highly favorable. Overall accuracy was 0.92, and j statistic was 0.88 (95% CI 0.79-0.94), consistent with our previous investigations [14] , and considered a 'near perfect' level of agreement supplementary Table S5B , available at Annals of Oncology online [18] . Supplementary Table S6 , available at Annals of Oncology online, describes patients' characteristics of the cohort for which we had both specimens; the sensitivity, specificity, PPV and NPV as measured within ProMisE subtype are shown in supplementary  Table S7 , available at Annals of Oncology online.
Discussion
Challenges with current systems of histomorphological classification and risk group stratification of EC are well known: (i) high 
OS). (C) Disease-specific survival (DSS). (D) Progression-free survival (PFS). (E) Model validation by Harell's C-index demonstrating the ability to predict outcomes (OS, DSS and PFS) by application of
ProMisEþ/À other parameters tested. (F) Crosstabulation of ProMisE molecular subtypes and ESMO 2013 risk groups, demonstrating the diversity within subtypes; ESMO high-as well as low-risk patients are present across all ProMisE subgroups. [14, 19, 20] , (iii) late information (post definitive surgical staging) with which to guide management [21] , and (iv) low accuracy in stratifying risk of recurrence or nodal metastases in clinically low stage cancers [7, 22] . Driven to address these challenges, we have developed a molecular classification tool that provides biologically relevant information to better stratify ECs for both research and clinical applications. We previously published studies that supported the feasibility and prognostic discrimination of our molecular classifier Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) through the 'discovery' and 'confirmation' phases dictated by the IOM for the development of 'omics'-based biomarker tests. This study marks the successful completion of the last 'validation' step in this rigorous process. In contrast to the multitude of biomarker studies in the literature that do not progress to the clinical setting, we herein share the data supporting immediate progression of molecular classification to clinical trials. To our knowledge this classifier represents the first biomarker to emerge from the TCGA gynecologic cancer data that have followed the IOM process, with the potential for immediate testing in the clinical setting. This validation cohort (N ¼ 452) of ECs segregated into four distinct molecular subtypes. Our study demonstrated that $10% of ECs harbored POLE exonuclease domain mutations, associated with excellent outcomes in these women, which again independently confirms many other studies in the literature [10, 16, [23] [24] [25] . This is in contrast with the very poor outcomes observed in women with p53abn ($11%) tumors. The two intermediate survival curves were overall consistent with the discovery and confirmation cohorts; patients with MMR-D tumors (28%) exhibiting worse OS, DSS, and PFS when compared with p53wt ($51% of cohort), however, the differences in these curves were less marked in this validation cohort. Previously published series on molecular classification of EC's [11, 13, 16] show variations with respect to these two intermediate-outcome molecular subtypes. This may be attributable to differences in composition or management of their respective cohorts.
This validation series reinforces previous observations on patient phenotype and pathological features corresponding to specific molecular subtypes, e.g. older age, lower BMI, high-grade for p53abn. Women with ECs harboring POLE EDMs were younger than those with other subtypes, and thinner than women with MMR-D and p53wt ECs. One notable difference in this cohort was the lower proportion of grade 3 endometrioid carcinomas within the POLE subgroup; 14% G3 in this series when compared with >50% in the previously published literature [16, 24, 26] . This may be attributed to differences in grade assignment between centers (21% of total cohort in Tübingen assigned grade 3 when compared with 61% in Vancouver), and consistent with previous observations on interobserver variability of this parameter. Reassuringly, the absolute percentage of ECs with POLE EDMs identified ($10%) and consistently favorable outcomes observed were identical to what was seen previously.
Approximately 2% of cases in our cohort of 452 women were found to have more than one molecular feature of ProMisE, consistent with a rate of <3%, 'double positives' previously reported [16] . Further studies are required to understand the implications of 'double positive status'.
The ability of ProMisE to discern outcomes, as measured by the Harrel's C-Index ( Figure 1E ) is highly favorable across all outcome parameters tested. It appears the addition of select cliniopathological parameters or ESMO risk group further improves the prognostic ability of this tool. The favorable C-Index of ESMO risk classifier is noted, however, ESMO risk group cannot be assigned until after surgical staging is carried out (requires surgical stage and, for 2016 criteria, also LVSI), while ProMisE provides the substantial advantage of being able to be assessed on diagnostic biopsy samples [13, 14] providing early information, from the time cancer is first diagnosed.
We have demonstrated the concordant ProMisE subtype assignment between diagnostic endometrial specimens (e.g. curettage), taken pre-staging, and final post-staging hysterectomy samples. The j statistic of 0.88 far exceeds the agreement observed in historical series for grade and histotype assignment, between these types of specimens [27, 28] . By performing molecular classification on diagnostic specimens patients and their physicians will have biologically relevant information from the earliest time point. This information will factor into decisionmaking regarding patient care, including identification of molecular subtypes that are more likely to benefit from checkpoint inhibitors, or less likely to respond to non-surgical management with high dose progestin therapy.
Next steps will focus on determining the optimal utilization of ProMisE in clinical trials. Ongoing collaborative research efforts are needed to determine parameters that will further strengthen ProMisE, and ultimately how molecular classification can guide fertility sparing treatments, surgery, adjuvant therapy, and surveillance in order to improve outcomes for women with EC. Firth confidence intervals were computed using the profile likelihood and may not match the LRT P-values.
(F) indicates that the Firth's penalized maximum likelihood bias reduction method was used to estimate the hazard ratio and the corresponding 95% confidence intervals were obtained using the penalized likelihood method. Bolded P-values indicate statistical significance at the 0.05 level.
